




GPPAD - The Global Platform for the
Prevention of Autoimmune Diabetes



**WE RESEARCH.
WITH PASSION.**

For a world without
type 1 diabetes.

Supported by

THE LEONA H. AND HARRY B.
HELMSLEY
CHARITABLE TRUST

**HELMHOLTZ
MUNICH**



**A WORLD
WITHOUT**



**A WORLD
WITHOUT**

WHO ARE WE

The **G**lobal **P**latform for the **P**revention of **A**utoimmune **D**iabetes (GPPAD) was initiated in 2015. It is an association of several renowned European research institutions providing an international infrastructure that enables type 1 diabetes primary prevention trials.

OUR VISION

Our long-term vision is to stop the trend of an increasing incidence of childhood type 1 diabetes. There must be global action built around a platform that coordinates controlled prevention trials. Our vision requires the participation and engagement of clinicians, scientists, government, laypersons, and the public at large to prevent a lifelong disease that affects 4 in every 1000 children.

WHAT WE DO

Our effort is focused on prevention of the autoimmunity that precedes and destroys the insulin-producing beta cells in the pancreas, eventually leading

to type 1 diabetes. Any intervention aiming to prevent type 1 diabetes has to start in infancy or earlier to avert the autoimmunity that often presents at 9 to 24 months of age. We facilitate this by establishing screening programs for the early detection of an increased genetic risk of type 1 diabetes in newborns, such as the Freder1k study in Germany (Bavaria, Lower Saxony and Saxony) and Belgium, the ASTR1D study in Sweden (Skåne region), the INGR1D study in the UK (Newcastle and Oxford region) and the newborn screening in Poland (Voivodship Mazowieckie). The screening program includes a genetic risk score that can identify newborns whose risk of developing the early signs of type 1 diabetes by age 6 years is 1 in 10 or higher.


PREVENTION INITIATIVE: SINT1A and POInT

We are working on developing new treatment approaches in the early stages that aim to prevent type 1 diabetes or at least delay its onset. With POInT (**P**imary **O**ral **I**nsulin **T**rial, ClinicalTrials.gov Identifier: NCT03364868) we are testing

whether daily administration of oral insulin can prevent the autoimmunity that leads to type 1 diabetes in children with an increased genetic risk for this disease. Recruiting for POInT was completed March 2021. First results are expected in 2024. With SINT1A (**S**upplementation

with B. **I**nfantis for Mitigation of **T**ype 1 Diabetes **A**utoimmunity, ClinicalTrials.gov Identifier: NCT04769037) we are testing whether daily supplementation of B. infantis can reduce the incidence of islet autoimmunity. Recruiting for SINT1A is ongoing.

GPPAD SITES IN EUROPE



GERMANY >> BAVARIA

Lead investigator:
Prof. Anette-Gabriele Ziegler &
Dr Christiane Winkler
Helmholtz Munich,
Ingolstädter Landstraße 1,
85764 Neuherberg
Phone: 0800-00 00 018
Email: cc@gppad.org

GPPAD Coordinating Center
Phone: 00800-33 15 33 15
Email: cc@gppad.org

GERMANY >> SAXONY

Lead investigator:
Prof. Ezio Bonifacio &
Prof. Dr Reinhard Berner
DFG Research Center for
Regenerative Therapies
Dresden (CRTD)
Technische Universität Dresden
Fetscherstraße 105,
01307 Dresden
Tel.: 0800-72 45 148
Email: diabetesstudie.crt@tu-dresden.de

GERMANY >> LOWER SAXONY

Lead investigator:
Prof. Dr Olga Kordonouri &
Prof. Dr Thomas Danne
Kinder- und Jugendkranken-
haus AUF DER BULT,
Janusz – Korczak – Allee 12,
30173 Hannover
Phone: 0800-37 33 37 15
Email: freder1k@hka.de

BELGIUM

Lead investigator:
Prof. Kristina Casteels
UZ Leuven, Gasthuisberg
Herestraat 49, 3000
Leuven
Phone: +32-(0)-16-348554
Email: freder1kstudie@uzleuven.be

POLAND

Lead investigator:
Dr Agnieszka Szypowska &
Dr Mariusz Ołtarzewski
Oddział Kliniczny Diabetologii
Dziecięcej i Pediatrii
Samodzielny Publiczny
Dziecięcy Szpital Kliniczny
ul. Żwirki i Wigury 63 A
02-091 Warszawa
Phone: +48-(0)-22 317 94 44
Email: kontakt@swiatbezdynki.pl

SWEDEN

Lead investigator:
Prof. Helena Elding Larsson &
Prof. Dr Markus Lundgren
Clinical Research Centre,
Lunds Universitet,
Hus 60, plan 11
Jan Waldenströms gata 35,
214 28 Malmö
Phone: +46-(0)-40-39 11 33
Email: gppad@med.lu.se

UK >> OXFORD

Lead investigator:
Dr Rachel Besser
Department of Paediatrics,
University of Oxford
Recruiting site: The Women's
Centre, John Radcliffe Hospital
Oxford, OX3 9DU
Phone: +44-(0)-1865-572258
Email: INGR1D@wrh.ox.ac.uk

UK >> NEWCASTLE

Lead investigator:
Prof. Steve Robson &
Dr Catherine Owen
Paediatric CRF
Research Office - Ward 1B
Newcastle upon Tyne Royal
Victoria Infirmary NE1 4LP
Phone: +44-(0)-191-2820553
Email: sharon.king10@nhs.net